Clinical Trials Logo

Acute Myeloid Leukemia clinical trials

View clinical trials related to Acute Myeloid Leukemia.

Filter by:

NCT ID: NCT00279773 Terminated - Clinical trials for Acute Myeloid Leukemia

Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia

Start date: September 2004
Phase: Phase 1
Study type: Interventional

The primary objective is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of TKI258 when administered to subjects with acute myeloid leukemia (AML).

NCT ID: NCT00276159 Terminated - Multiple Myeloma Clinical Trials

Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

Start date: January 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat certain hematologic malignancies not responding to standard treatment.

NCT ID: NCT00273884 Completed - Clinical trials for Acute Myeloid Leukemia

Amonafide in Combination With Cytarabine in Secondary AML

Start date: August 2005
Phase: Phase 2
Study type: Interventional

This protocol is designed to assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.

NCT ID: NCT00266136 Completed - Clinical trials for Acute Myeloid Leukemia

Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)

Start date: June 1999
Phase: Phase 3
Study type: Interventional

The study in patients with primary and secondary AML and high-risk MDS uses a risk-stratified, randomized design to evaluate the role of high-dose araC in induction, of G-CSF priming, and of autologous stem cell transplantation.

NCT ID: NCT00260832 Completed - Clinical trials for Acute Myeloid Leukemia

Trial of Decitabine in Patients With Acute Myeloid Leukemia

Start date: November 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the results in older patients who have newly diagnosed or secondary acute myeloid leukemia (AML) and who are to either receive decitabine or patient's choice with the physician's advice of either cytarabine or supportive care medication.

NCT ID: NCT00255346 Completed - Clinical trials for Acute Myeloid Leukemia

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Start date: November 15, 2005
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.

NCT ID: NCT00242515 Recruiting - Clinical trials for Acute Myeloid Leukemia

T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Start date: March 2005
Phase: Phase 1/Phase 2
Study type: Interventional

Primary Objectives: This a pilot project to determine the feasibility of the preemptive CD8+ depleted T-cell donor lymphocyte infusion (DLI) in: - Reducing the incidence of graft versus host disease (GVHD) based on standard classification of acute and chronic GVHD - Improving hte disease remission rate in comparison with our previous study results. Secondary Objectives: - To investigate the impact of CD8+ depleted T-cell DLI in hematopoietic chimerism, and immunologic recovery of transplant patients.

NCT ID: NCT00235560 Completed - Clinical trials for Acute Myeloid Leukemia

Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients

LAM-RAPA
Start date: June 2005
Phase: Phase 2
Study type: Interventional

These study is designed to evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin in elderly AML.

NCT ID: NCT00226512 Withdrawn - Clinical trials for Acute Myeloid Leukemia

To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning

Start date: July 2004
Phase: Phase 3
Study type: Interventional

Multi-institutional randomized phase III trial of a non-myeloablative preparative regimen with fludarabine and busulfex with or without anti-lymphocyte antibodies (monoclonal humanized Campath-1H administered s.c. or polyclonal rabbit anti-T lymphocyte antibodies (ATG), combined with low dose and short course cyclosporine A (CSA) and methotrexate (MTX) as the sole agent for prevention of graft-vs-host disease (GVHD) for patients with acute myelogenous leukemia or myelodysplastic syndrome undergoing allogeneic stem cell transplantation from an HLA compatible donor.

NCT ID: NCT00199147 Recruiting - Clinical trials for Acute Myeloid Leukemia

Efficacy of G-CSF-Priming in Elderly AML Patients

Start date: January 2000
Phase: Phase 4
Study type: Interventional

Aim of the study is to compare the efficacy of intensive induction therapy with Cytarabine, Idarubicin and Etoposide (IdAV) given in parallel with (G-CSF priming) and followed by G-CSF versus the same IdAV chemotherapy only followed by G-CSF (without priming) in elderly patients with de novo AML, secondary AML and advanced MDS. Moreover, the ability to mobilize sufficient numbers of peripheral blood stem cells (PBSC) for autologous PBSC transplantation after consolidation therapy with dose-reduced FLAG-Ida chemotherapy followed by G-CSF will be evaluated.